Fundación Pasqual Maragall evaluated a prototype Beckman Coulter Access brain-derived p-tau217 immunoassay run on the DxI 9000 automated analyser.
Public source
Publisher name
Public post
An Alzheimer’s blood test can be accurate—and still leave too many patients in the grey zone. A new study suggests that making the measurement more brain-selective could…
Company
Fundación Pasqual Maragall
Por un futuro sin Alzheimer / A future without Alzheimer's
- Industry
- Research
- Location
- Barcelona, ES
- Company size
- 201–500 employees
About Fundación Pasqual Maragall
At the Pasqual Maragall Foundation we are working towards a future without Alzheimer’s. Our research focuses on how to stop this disease and prevent its progress before the onset of symptoms, given that any damage it causes in the brain begins decades before the disease manifests itself. We also help to improve the lives of people with the disease and their families by offering therapy groups for caregivers. The Foundation also works to raise the public’s awareness on the effects and consequences of Alzheimer’s and to obtain support for scientific research in this field - the only strategy that will provide us with solutions to these challenges. Our scientific activity is carried out through our research institute, the Barcelonaβeta Brain Research Centre, a one-of-a-kind advanced research institution working in collaboration with Pompeu Fabra University. The aim of this centre is to conduct clinical research on the prevention of Alzheimer’s disease and associated cognitive functions in both healthy and pathological ageing. Our facility offers a range of equipment, including a neuroimaging platform with a state-of-the-art 3T MRI machine, used for obtaining and processing high-quality images of the brain. Although the Pasqual Maragall Foundation is young, it is now well-established and enjoying growth. At present, there are more than 65 employees working for us, a team consisting of researchers, technicians and professionals from the fields of medicine, psychology, biology, and nursing. The foundation also has financial, purchasing, human resources, communication, fund-raising, maintenance and IT departments. And we are not alone. More than 2,700 people altruistically participate in the research studies conducted by our foundation, which also has a network of 15,000 members and contributors. If you wish to join our team, please visit our website to learn more about our foundation and see our latest job vacancies: https://fpmaragall.org/en/work-with-us/
See moreLatest activity
Latest activity from Fundación Pasqual Maragall
4 signals
Presence & Recognition
Fundación Pasqual Maragall hosted a meeting with director Miquel Antonijuan of Molins LR to discuss a strategic filantrophy initiative.
Strategy & Corporate Development
Fundación Pasqual Maragall established a new Innovation Unit at the Barcelona Brain Research Center to support its innovation strategy and knowledge transfer.
Research & Knowledge
Fundación Pasqual Maragall promotes the ALFA+ longitudinal study part of the ALFA Study led by the Barcelonaβeta Brain Research Center, providing a unique resource for studying the earliest biological changes associated with Alzheimer’s disease.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Diasorin
Diasorin reported that plasma p-tau217 moved primary care physicians from roughly 65% to 93% accuracy in suspected Alzheimer’s off a routine blood draw.
Research & Knowledge
Spear Bio
Spear Bio published preliminary data showing that the SPEAR TrueDetect eMTBR-Tau Assay demonstrated increased plasma eMTBR-Tau specifically in Tau-positive samples, minimal response to amyloid positivity, 100% detectability above the functional LLoD, and 99.2% quantifiability above the functional LLoQ.
Research & Knowledge
Alzheimer's Disease Data Initiative
Alzheimer's Disease Data Initiative published a study by Guglielmo di Molfetta and co-authors of Banner Health identifying an alternative diagnostic pathway for advanced Alzheimer's pathology using a new blood test panel that improved diagnostic accuracy and reduced ambiguous results.
Research & Knowledge
Roche Diagnostics UK & Ireland
Roche Diagnostics UK & Ireland published new research from the Alzheimer's Society showing that nearly half of surveyed individuals waited more than six months for an accurate dementia diagnosis after visiting their GP.
Research & Knowledge
Elion Medical Communications